X4 PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: To elect the one (1) nominee named in the accompanying proxy statement (the "Proxy Statement"), R. Keith Woods, to the Board of Directors to hold office until the 2028 Annual Meeting of Stockholders and until his successor is duly elected and qualified until his earlier death, resignation or removal: R. Keith Woods

X4 PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: R. Keith Woods”): 52,191,014 for, 29,872,082 withheld, per its Form 8-K filed June 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 26 asset managers below reported 10,428,022 for, 478,400 withheld.

Showing the 25 largest of 26 asset managers. All 26 are in the interactive database (link above).

Description as filed by funds: To approve an amendment to our Restated Certificate of Incorporation, as amended to combine outstanding shares of our common stock, par value $0.001 per share, into a lesser number of outstanding shares (the "Reverse Stock Split"), by a ratio of not less than one-for-fifteen and not more than one-for-thirty, with the exact ratio to be set within this range by our board of directors in its sole discretion.

X4 PHARMACEUTICALS INC.’s own tally for this item (“1. The approval of an amendment to our Restated Certificate of Incorporation, as amended ("Certificate of Incorporation") to combine outstanding shares of our Common Stock into a lesser number of outstanding shares (the ”): 113,027,737 for, 23,988,610 against, per its Form 8-K filed April 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Voting standard, as the filing states it: a supermajority of the shares outstanding (“79% of the shares issued and outstanding”).

The 25 asset managers below reported 10,708,901 for.

Description as filed by funds: TO APPROVE AN ADJOURNMENT OF THE SPECIAL MEETING, IF NECESSARY, TO PERMIT FURTHER SOLICITATION AND VOTE OF PROXIES IN THE EVENT THAT THERE ARE INSUFFICIENT VOTES IN FAVOR OF PROPOSAL NO. 1 (THE REVERSE STOCK SPLIT).

The 25 asset managers below reported 10,559,677 for, 149,224 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: To hold a non-binding, advisory "say-on-pay" vote on the Company's executive compensation.

X4 PHARMACEUTICALS INC.’s own tally for this item (“3. Non-Binding Advisory "Say-On-Pay" Vote on Named Executive Officer Compensation”): 67,793,970 for, 12,234,847 against — passed, per its Form 8-K filed June 11, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Non-Binding Advisory "Say-On-Pay" Vote on Named Executive Officer Compensation The Company's stockholders approved, by a non-binding "say-on-pay" vote, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement relating to the An…”
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 26 managers: 10,094,085 for, 812,337 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports, all 64 managers: 52,899,793 for, 3,399,831 against. Showing the 25 largest; every one is in the interactive database (link above).

Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.

X4 PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 128,889,553 for, 6,595,740 against — passed, per its Form 8-K filed June 11, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the Company's independent registered public accounting firm for the fiscal …”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 26 asset managers below reported 10,905,747 for, 675 against.

Showing the 25 largest of 26 asset managers. All 26 are in the interactive database (link above).